Announcements Trials
Browse Landscape

Phase

Phase 1/2 8Phase 2 3Phase 3 2Phase 1 2

Status

Unknown 1Terminated 1Completed 1

Sponsor Class

INDUSTRY 4OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3

Conditions

Leukemia, Myeloid, Acute 3

Interventions

Cisplatin 1041Cyclophosphamide 973Carboplatin 954Radiotherapy 893Bevacizumab 847Gemcitabine 817pembrolizumab 759Paclitaxel 738Docetaxel 734Oxaliplatin 706Capecitabine 648Fluorouracil 564Rituximab 559Nivolumab 506Dexamethasone 487Etoposide 468Doxorubicin 458Irinotecan 442Drug Therapy 402Leucovorin 377Cytarabine 342Cetuximab 340Lenalidomide 326Trastuzumab 323Pemetrexed 315durvalumab 295Filgrastim 287Magnetic Resonance Spectroscopy 278Temozolomide 275Prednisone 273

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × OTHER × quizartinib × Clear all
NCT04107727 2026-03-24

Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)

PETHEMA Foundation

Phase 2 Completed
273 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04209725 2023-12-05

A Study of CPX-351 (Vyxeosâ„¢) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia

SCRI Development Innovations, LLC

Phase 2 Terminated
1 enrolled 7 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03135054 2020-12-10

Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITD

The University of Hong Kong

Phase 2 Unknown
40 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡